Company Overview
Zymeworks is a private Canadian computational biotechnology company founded in the spring of 2004.
Zymeworks’ core business focus is to develop a pipeline of enabling enzymes for the chemical industry and protein therapeutics for the pharmaceutical industry. This is accomplished through internal research and development, and strategic partnerships with established companies in the field.
Zymeworks’ core competency is in altering enzyme substrate specificity and improving antibody binding affinities. The Zymeworks Computer Assisted Design (ZymeCAD™) molecular simulation technology creates a highly detailed computational modeling environment for accurate and predictive semi-rational protein engineering. This technology is used by our scientists to generate the necessary physical and chemical insight required to address market needs.